Report #2894926

Received Apr 30, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 21 yrs
State: MD
Recovered: Unknown
Vaccinated: Apr 20, 2026
Onset: Apr 20, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEPA	HEP A (HAVRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	MZ474	—

Symptoms (1)

Underdose

Symptom narrative

child dose of Havrix was administered to an adult patient; Administration of less than the recommended dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 21-year-old male patient who received HAV (Havrix 720) (batch number MZ474, expiry date 24-APR-2026) for prophylaxis. Previously administered products included Havrix 720 (received the first dose of Havrix 720). On 20-APR-2026, the patient received the 2nd dose of Havrix 720. On 20-APR-2026, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: child dose of Havrix was administered to an adult patient) and underdose (Verbatim: Administration of less than the recommended dose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.